Angelina Jolie's case highlights the importance of knowing …
Advertisement
Pfizer says Torisel-Avastin failed in cancer study
No difference in disease progression
Updated: Friday, 10 Aug 2012, 4:37 PM EDT
Published : Friday, 10 Aug 2012, 4:37 PM EDT
NEW YORK (AP) - Pfizer said Friday that its drug Torisel failed to help patients with a form of advanced kidney cancer when combined with Roche's drug Avastin.
The study compared renal cell carcinoma patients taking the Torisel-Avastin combination to those taking Avastin plus another cancer drug.
Patients taking the Pfizer combination did not show slower disease progression than those in the other group. Pfizer said.
Torisel is already approved as a stand-alone treatment for advanced renal cell carcinoma.
 | With WDTN.com's new commenting system you don't need to register. You can login with an existing Facebook, Yahoo!, Google, or Twitter account and more. |
Email This
Print This
View Story on a Single Page
Advertisement
Mugshot Gallery
The following people have recently been booked into Jail. They may not have been convicted of the crimes they are charged with and are innocent until proven guilty.
Advertisement
Advertisement